{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:42:42Z","timestamp":1790757762438,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1998,12]]},"DOI":"10.1212\/wnl.51.6.1703","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:37:14Z","timestamp":1336916234000},"page":"1703-1708","source":"Crossref","is-referenced-by-count":45,"title":["Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS"],"prefix":"10.1212","volume":"51","author":[{"given":"I.","family":"Elovaara","sequence":"first","affiliation":[{"name":"From the Neuroimmunology Unit (Drs. Elovaara and La\u0308lla\u0308, and E. Spa\u030are), Department of Neurology, the Department of Clinical Chemistry (Dr. Lehtima\u0308ki), Research Laboratory for Atherosclerosis, and the Department of Diagnostic Radiology (Dr. Dastidar), Tampere University Hospital, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"La\u0308lla\u0308","sequence":"additional","affiliation":[{"name":"From the Neuroimmunology Unit (Drs. Elovaara and La\u0308lla\u0308, and E. Spa\u030are), Department of Neurology, the Department of Clinical Chemistry (Dr. Lehtima\u0308ki), Research Laboratory for Atherosclerosis, and the Department of Diagnostic Radiology (Dr. Dastidar), Tampere University Hospital, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Spa\u030are","sequence":"additional","affiliation":[{"name":"From the Neuroimmunology Unit (Drs. Elovaara and La\u0308lla\u0308, and E. Spa\u030are), Department of Neurology, the Department of Clinical Chemistry (Dr. Lehtima\u0308ki), Research Laboratory for Atherosclerosis, and the Department of Diagnostic Radiology (Dr. Dastidar), Tampere University Hospital, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lehtima\u0308ki","sequence":"additional","affiliation":[{"name":"From the Neuroimmunology Unit (Drs. Elovaara and La\u0308lla\u0308, and E. Spa\u030are), Department of Neurology, the Department of Clinical Chemistry (Dr. Lehtima\u0308ki), Research Laboratory for Atherosclerosis, and the Department of Diagnostic Radiology (Dr. Dastidar), Tampere University Hospital, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dastidar","sequence":"additional","affiliation":[{"name":"From the Neuroimmunology Unit (Drs. Elovaara and La\u0308lla\u0308, and E. Spa\u030are), Department of Neurology, the Department of Clinical Chemistry (Dr. Lehtima\u0308ki), Research Laboratory for Atherosclerosis, and the Department of Diagnostic Radiology (Dr. Dastidar), Tampere University Hospital, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","first-page":"4","volume":"97","year":"1994","unstructured":"Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multiple step paradigm. Cell 1994;97:46-51.","journal-title":"Cell"},{"key":"e_1_3_1_3_2","first-page":"2","volume":"6","year":"1996","unstructured":"Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996;6:243-257.","journal-title":"Brain Pathol"},{"key":"e_1_3_1_4_2","first-page":"2","volume":"40","year":"1992","unstructured":"Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T-cell production of interferon-gamma. J Neuroimmunol 1992;40:211-218.","journal-title":"J Neuroimmunol"},{"key":"e_1_3_1_5_2","first-page":"7","volume":"17","year":"1995","unstructured":"Lassmann H, Vass K. Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Springer Semin Immunopathol 1995;17:77-87.","journal-title":"Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Springer Semin Immunopathol"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(88)90107-5"},{"key":"e_1_3_1_7_2","first-page":"4","volume":"37","year":"1995","unstructured":"Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_8_2","first-page":"3","volume":"31","year":"1992","unstructured":"Rossler K, Neuchrist C, Kitz K, Scheiner O, Kraft D, Lassmann H. Expression of leukocyte adhesion molecules at the human blood-brain barrier (BBB). J Neurosci Res 1992;31:365-374.","journal-title":"J Neurosci Res"},{"key":"e_1_3_1_9_2","first-page":"1","volume":"136","year":"1990","unstructured":"Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the central nervous system. Am J Pathol 1990;136:1309-1316.","journal-title":"Am J Pathol"},{"key":"e_1_3_1_10_2","first-page":"5","volume":"177","year":"1993","unstructured":"Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into the brain parenchyma. J Exp Med 1993;177:57-68.","journal-title":"J Exp Med"},{"key":"e_1_3_1_11_2","first-page":"9","volume":"72","year":"1997","unstructured":"Soilu-H\u00e4nninen M, R\u00f6ytt\u00e4 M, Salmi A, Salonen RJ. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol 1997;72:95-105.","journal-title":"J Neuroimmunol"},{"key":"e_1_3_1_12_2","first-page":"6","volume":"356","year":"1992","unstructured":"Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4\u03b21 integrin. Nature 1992;356:63-66.","journal-title":"Nature"},{"key":"e_1_3_1_13_2","first-page":"1","volume":"1","year":"1991","unstructured":"Lassmann H, Rossler K, Zimprich F, Vass K. Expression of adhesion molecules and histocompatibility antigens at the blood-brain barrier. Brain Pathol 1991;1:115-123.","journal-title":"Brain Pathol"},{"key":"e_1_3_1_14_2","first-page":"8","volume":"35","year":"1994","unstructured":"Washington R, Burton J, Todd RF, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994;35:89-97.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_15_2","first-page":"3","volume":"53","year":"1994","unstructured":"Raine CS. Multiple sclerosis: immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994;53:328-337.","journal-title":"J Neuropathol Exp Neurol"},{"key":"e_1_3_1_16_2","first-page":"2","volume":"36","year":"1986","unstructured":"Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986;36:238-243.","journal-title":"Neurology"},{"key":"e_1_3_1_17_2","first-page":"5","volume":"50","year":"1987","unstructured":"Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. I. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307013290101"},{"key":"e_1_3_1_19_2","first-page":"6","volume":"42","year":"1992","unstructured":"Barkhof F, Frequin STFM, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-67.","journal-title":"Neurology"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.1.1"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410340102"},{"key":"e_1_3_1_22_2","first-page":"2","volume":"50","year":"1998","unstructured":"Droogan AG, Crockard AD, McMillan SA, Hawkins SA. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS. Neurology 1998;50:224-230.","journal-title":"Neurology"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130103"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.1.1"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(93)90261-V"},{"key":"e_1_3_1_26_2","first-page":"2","volume":"39","year":"1985","unstructured":"von Willebrand E, Zola H, H\u00e4yry P. Thrombocyte aggregates in renal allografts. Analysis with fine-needle aspiration biopsy and monoclonal antithrombocyte antibodies. Transplantation 1985;39:258-262.","journal-title":"Transplantation"},{"key":"e_1_3_1_27_2","first-page":"9","volume":"89","year":"1992","unstructured":"Cronstein BN, Kimmel SC, Levin RI, Martiniuk. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule-1. Proc Natl Acad Sci USA 1992;89:9991-9995.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(93)90068-A"},{"key":"e_1_3_1_29_2","first-page":"2","volume":"43","year":"1993","unstructured":"Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993;43:2679-2682.","journal-title":"Neurology"},{"key":"e_1_3_1_30_2","first-page":"2","volume":"44","year":"1994","unstructured":"Rieckmann P, Martin S, Weichselbraun I, et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 1994;44:2367-2372.","journal-title":"Neurology"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370104"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380102"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(95)00141-7"},{"key":"e_1_3_1_34_2","first-page":"3","volume":"41","year":"1997","unstructured":"Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326-333.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.1"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/121.1.3"},{"key":"e_1_3_1_37_2","first-page":"6","volume":"41","year":"1997","unstructured":"Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon-1b. Ann Neurol 1997;41:669-674.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_38_2","first-page":"8","volume":"19","year":"1994","unstructured":"de Waal RMW. The anti-inflammatory activity of glucocorticoids. Mol Biol Rep 1994;19:81-88.","journal-title":"Mol Biol Rep"},{"key":"e_1_3_1_39_2","first-page":"9","volume":"70","year":"1996","unstructured":"McCombe PA, Nickson I, Tabi Z, Pender MP. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V\u03b28.2- and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V\u03b28.2-cells. J Neuroimmunol 1996;70:93-101.","journal-title":"J Neuroimmunol"},{"key":"e_1_3_1_40_2","first-page":"4","volume":"143","year":"1989","unstructured":"Nieto MA, Lopez-Rivas A. IL-2 protects T-lymphocytes from glucocorticoid-induced DNA fragmentation and cell death. J Immunol 1989;143:4166-4170.","journal-title":"J Immunol"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.149.1.1"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240102"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.51.6.1703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T16:08:04Z","timestamp":1711555684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.51.6.1703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["10.1212\/WNL.51.6.1703"],"URL":"https:\/\/doi.org\/10.1212\/wnl.51.6.1703","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}